Quarterly ResultMay 13, 2026, 08:17 AM
Protara Therapeutics Q1 Net Loss Widens to $17.78M; Clinical Trial Update
AI Summary
Protara Therapeutics reported a net loss of $17.78 million for the first quarter of 2026, an increase from $11.91 million in the same period last year, driven by higher research and development expenses. Despite the increased cash burn, the company stated it has sufficient financial resources to meet its liquidity needs for at least the next 12 months. Additionally, a significant clinical trial milestone was achieved, fixing the exercise termination date for certain common warrants.
Key Highlights
- Net loss widened to $17.78 million for Q1 2026, compared to $11.91 million in Q1 2025.
- Research and development expenses increased to $13.56 million in Q1 2026 from $9.15 million YoY.
- Cash and cash equivalents decreased to $14.74 million as of March 31, 2026, from $49.66 million.
- Net cash used in operating activities increased to $21.34 million in Q1 2026 from $14.71 million YoY.
- Protara Therapeutics believes current financial resources are sufficient for at least 12 months of liquidity.
- Exercise termination date for April 2024 Common Warrants fixed to June 29, 2026, after ADVANCED-2 trial condition met.
- Approximately 971 Series 1 Convertible Preferred Stock shares converted into 971,204 common shares in Q1 2026.
- Subsequent to Q1, 3,772 Series 1 Preferred Stock shares converted into 3,773,586 common shares.
Price Impact
More from TARA